Case Study: autoCUT&RUN Accelerates PROTAC Drug Development
autoCUT&RUN Accelerates PROTAC Drug Development
Case Study
PROTACs targeting transcriptional regulators are advancing quickly, but many programs still lack direct evidence of mechanism of action (MoA). Traditional assays such as RNA-seq show downstream effects but fail to demonstrate what exactly is happening on the chromatin level, where these targets function. EpiCypher’s CUTANA™ Genomic Services are helping address this gap.
In a recent case study, autoCUT&RUN directly measured chromatin engagement of a SMARCA2 degrader:
• Confirmed on-target depletion
• Ruled out key off-target activity
• Linked mechanism to disease-relevant loci
CUT&RUN is a part of EpiCypher’s broader CUTANA™ platform that includes complementary DNA methylation, Fiber-seq, and emerging ATAC-seq and FFPE profiling assays. Our industry-validated assays and services help connect chromatin changes to gene expression. Instead of merely observing change, you can directly prove the mechanism of action.
If you are developing a PROTAC drug, let us connect and discuss how to generate decision-enabling MoA data!
